Belfiori-Carrasco Lautaro F, Marcora María S, Bocai Nadia I, Ceriani M Fernanda, Morelli Laura, Castaño Eduardo M
Laboratorio de Amiloidosis y Neurodegeneración, Fundación Instituto Leloir-Instituto de Investigaciones Bioquímicas de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) Buenos Aires, Argentina.
Laboratorio de Genética del Comportamiento, Fundación Instituto Leloir-Instituto de Investigaciones Bioquímicas de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) Buenos Aires, Argentina.
Front Aging Neurosci. 2017 Mar 14;9:61. doi: 10.3389/fnagi.2017.00061. eCollection 2017.
The accumulation of amyloid β peptide (Aβ) in the brain of Alzheimer's disease (AD) patients begins many years before clinical onset. Such process has been proposed to be pathogenic through the toxicity of Aβ soluble oligomers leading to synaptic dysfunction, phospho-tau aggregation and neuronal loss. Yet, a massive accumulation of Aβ can be found in approximately 30% of aged individuals with preserved cognitive function. Therefore, within the frame of the "amyloid hypothesis", compensatory mechanisms and/or additional neurotoxic or protective factors need to be considered and investigated. Here we describe a modifier genetic screen in designed to identify genes that modulate toxicity of Aβ42 in the CNS. The expression of Aβ42 led to its accumulation in the brain and a moderate impairment of negative geotaxis at 18 days post-eclosion (d.p.e) as compared with genetic or parental controls. These flies were mated with a collection of lines carrying chromosomal deletions and negative geotaxis was assessed at 5 and 18 d.p.e. Our screen is the first to take into account all of the following features, relevant to sporadic AD: (1) pan-neuronal expression of wild-type Aβ42; (2) a quantifiable complex behavior; (3) Aβ neurotoxicity associated with progressive accumulation of the peptide; and (4) improvement or worsening of climbing ability only evident in aged animals. One hundred and ninety-nine deficiency (Df) lines accounting for ~6300 genes were analyzed. Six lines, including the deletion of 52 genes with human orthologs, significantly modified Aβ42 neurotoxicity in 18-day-old flies. So far, we have validated and identified as a strong candidate (whose human orthologs are and , respectively) by using RNAi or mutant hemizygous lines. encodes proline-rich protein PRCC (ppPRCC) of unknown function associated with papillary renal cell carcinoma. encodes 4-hydroxyphenylpyruvate dioxygenase (HPPD), a key enzyme in tyrosine degradation whose Df causes autosomal recessive Tyrosinemia type 3, characterized by mental retardation. Interestingly, lines with a partial Df of ortholog showed increased intraneuronal accumulation of Aβ42 that coincided with geotaxis impairment. These previously undetected modifiers of Aβ42 neurotoxicity in warrant further study to validate their possible role and significance in the pathogenesis of sporadic AD.
阿尔茨海默病(AD)患者大脑中β淀粉样肽(Aβ)的积累在临床发病前许多年就已开始。有人提出,这种过程具有致病性,是通过Aβ可溶性寡聚体的毒性导致突触功能障碍、磷酸化tau蛋白聚集和神经元丢失。然而,在约30%认知功能保留的老年人中可发现大量Aβ积累。因此,在“淀粉样蛋白假说”的框架内,需要考虑并研究代偿机制和/或其他神经毒性或保护因素。在此,我们描述了一项在果蝇中进行的修饰基因筛选,旨在鉴定调节Aβ42在中枢神经系统中毒性的基因。与基因对照或亲本对照相比,Aβ42的表达导致其在大脑中积累,并在羽化后18天(d.p.e)时对负趋地性产生中度损害。这些果蝇与一系列携带染色体缺失的品系进行杂交,并在5 d.p.e和18 d.p.e时评估负趋地性。我们的筛选首次考虑了与散发性AD相关的以下所有特征:(1)野生型Aβ42的全神经元表达;(2)一种可量化的复杂行为;(3)与该肽的渐进性积累相关的Aβ神经毒性;以及(4)仅在老年动物中明显的攀爬能力改善或恶化。分析了199个缺失(Df)品系,约占6300个基因。6个品系,包括缺失52个具有人类同源基因的基因,显著改变了18日龄果蝇中Aβ42的神经毒性。到目前为止,我们通过使用RNA干扰或突变半合子品系验证并鉴定了一个强候选基因(其人类同源基因分别为和)。编码与乳头状肾细胞癌相关的功能未知的富含脯氨酸蛋白PRCC(ppPRCC)。编码4-羟基苯丙酮酸双加氧酶(HPPD),这是酪氨酸降解中的关键酶,其Df导致常染色体隐性遗传性3型酪氨酸血症,其特征为智力迟钝。有趣的是,具有同源基因部分Df的品系显示Aβ42在神经元内的积累增加,这与趋地性损害一致。这些先前未被检测到的Aβ42神经毒性修饰因子值得进一步研究,以验证它们在散发性AD发病机制中的可能作用和意义。